Instructor Notes — Chapter 24

PT-141 (Bremelanotide) and the Sexual Function Peptides · Part IV, closing chapter · intermediate · prerequisites 13, 21, 5

What this chapter is actually for

On the surface it is a chapter about four molecules. Underneath, it is doing three jobs that the rest of the book depends on.

Job one: recalibrating what ✅ means. This is the chapter's most important contribution and it is easy to miss. Most students arrive with an implicit reading of ✅ as "works well." Bremelanotide is the book's designated counterexample: strong evidential support, modest effect, common adverse effect, narrow population, and a behavioral endpoint that did not move. If students leave this chapter still reading ✅ as a magnitude claim, the remaining chapters will be systematically misread. Budget class time accordingly — this is worth more discussion than the receptor pharmacology.

Job two: a mechanistic distinction with immediate real-world value. §24.3 — central desire versus peripheral blood flow — is one of the few pieces of content in this book that will change what some students do next week. It is also widely gotten wrong by otherwise well-informed people. Teach it as a clinical sorting skill, not as pharmacology trivia.

Job three: a worked application of the case-report asymmetry. Chapter 5 §5.2 stated the principle; §24.6 is where students see it do work in a situation where the conclusion is genuinely uncomfortable — the evidence supports concern without supporting a number, and both overstating and dismissing are errors.

Time and sequencing

Estimated 6–8 hours of student time. For a seminar format, two sessions works better than one:

• Session A — §24.1–24.3 plus case study 1. Origin story, receptor map, and the central/peripheral distinction. Ends on a clean mechanistic note.
• Session B — §24.4–24.8 plus case study 2 and the dossier. Approval, effect size, the medicalization debate, melanotan II, kisspeptin, ratings.

If you have only one session, cut §24.7 to a five-minute summary and keep everything else. Kisspeptin is the least load-bearing section for later chapters.

Handling the subject matter

This is the chapter where classroom management matters most, and the failure mode is predictable.

Set the frame before the first section, not after the first joke. State plainly that sexual dysfunction is a legitimate medical concern that degrades quality of life, that it is under-discussed in clinical encounters because both parties find it awkward, and that the class will discuss it the way it would discuss any other functional complaint. Say that humor at patients' expense is out of bounds. This takes ninety seconds and it prevents most of what would otherwise go wrong.

Assume someone in the room has one of these complaints, or loves someone who does. This is not a hypothetical population. Statistically it is a near-certainty in any class of reasonable size.

Do not ask for personal disclosure, and shut down volunteers who begin to offer it. Redirect to the material. "That's exactly the kind of case the trials were designed around — let's look at what they found."

Cosmetic tanning invites moralizing, and moralizing here breaks rule 4. Some students will want to treat melanotan II users as foolish. The chapter explicitly declines to: the motivation — a tan without the carcinogenic exposure — is rational. Hold the line. The rating is about evidence, and if you let contempt in through the tanning discussion it will be much harder to keep it out of the HSDD discussion.

The HSDD debate will produce the strongest opinions in the chapter, often along predictable lines. The assignment is not to resolve it. It is to be able to state either position to its own advocates' satisfaction. Grade case study 2 on the quality of the steelmanning, and be explicit about that in advance.

Where students reliably get stuck

"So does bremelanotide work or not?" This question is the whole chapter. The answer is: the evidence supports the claim in the studied population, and the effect is modest. Students want one word and there isn't one. Resist supplying one — the discomfort is the learning.

Confusing "narrow approval" with "weak evidence." These are independent. Afamelanotide's approval is extremely narrow and the evidence is good. Narrowness is about scope, not strength — and §24.5 argues narrowness often makes a claim more trustworthy.

Overcorrecting on case reports. After Chapter 5, some students conclude that case reports are worthless, full stop. §24.6 requires the more sophisticated position. Watch for students who dismiss the melanotan II reports entirely; they have learned half the rule.

Reading the melanotan II ❌ as a judgment about tanning. Ask them: what would change this rating? If they can answer with "trials plus surveillance data," they have it. If they answer with "nothing," they have imported a verdict.

Assuming approvals run in families. The melanotan II Field 7 block flags this explicitly. Its structural near-twin is approved and its close relative is approved, and neither approval transfers.

Treating off-label prescribing as evidence. The dossier section addresses this directly and it still catches people. Off-label use is legal and often appropriate and generates no data.

Assessment guidance

• Quiz — 22 items, key included. Items 11, 13, 15, 19, and 20 are the discriminating ones; a student who gets those five right has the chapter. Item 19 distinguishes the two failure modes (overclaiming from case reports and dismissing them entirely) — worth reviewing aloud whichever way the class splits.
• Exercises — 34 items, ten marked †. A reasonable problem set is Part B in full plus items q, s, t†, x†, ah, ai†, and aj. Items z† and aa† (the two steelman paragraphs) are best assigned together or not at all.
• Case studies — case study 1 is the more accessible; case study 2 is the more demanding and the better summative assessment. Question 6 in case study 2 is the sharpest single item in the chapter's materials.
• A good short essay prompt: "✅ certifies evidential support, not effect magnitude. Explain, using two of this chapter's molecules, and then say what practical difference the distinction makes to a patient."